csl-360
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00401739)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-3 receptor subunit alphaINHIBITOR
IL3RA inhibitor
- Interleukin-3INHIBITOR
IL3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109327 ↗
Also known as
- csl360
- csl-360
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00401739 | Phase 1 | Dec 1, 2006 | CSL, Melbourne Health |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CSL | For profit | 1 | 1 | 1 | 2006 |
| Melbourne Health | Academic/Hospital | 1 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1